Peroxisome proliferator-activated receptor ␥ (PPAR-␥) activation in adipose tissue is known to regulate genes involved in adipocyte differentiation and lipid metabolism. However, the role of PPAR-␥ in muscle remains unclear. To examine the potential regulation of genes by PPAR-␥ in human skeletal muscle, we used semiquantitative RT-PCR to determine the expression of PPAR-␥, lipoprotein lipase (LPL), muscle carnitine palmitoyl transferase-1 (mCPT1), fatty acid-binding protein (FABP), carnitine acylcarnitine transferase (CACT), and glucose transporter-4 (GLUT4) in freeze-dried muscle samples from 14 male subjects. These samples were dissected free of adipose and other tissue contamination, as confirmed by minimal or absent adipsin expression. Between individuals, the messenger ribonucleic acid concentration of PPAR-␥ varied up to 3-fold, whereas LPL varied up to 6.5-fold, mCPT1 13-fold, FABP 4-fold, CACT 4-fold, and GLUT4 up to 3-fold. The expression of LPL (r 2 ϭ 0.54; P ϭ 0.003), mCPT1 (r 2 ϭ 0.42; P ϭ 0.012), and FABP (r 2 ϭ 0.324; P ϭ 0.034) all correlated significantly with PPAR-␥ expression in the same samples. No significant correlation was observed between the expression of CACT and PPAR-␥ or between GLUT4 and PPAR-␥. These findings demonstrate a relationship between PPAR-␥ expression and the expression of other genes of lipid metabolism in muscle and support the hypothesis that PPAR-␥ activators such as the antidiabetic thiazolidinediones may regulate fatty acid metabolism in skeletal muscle as well as in adipose tissue. (J Clin Endocrinol Metab 85: 4293-4297, 2000) 
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Recent studies indicate that thiazolidinediones (TZDs), a new class of antidiabetic drugs known to bind and activate PPAR-␥, enhance insulin sensitivity in humans with insulin resistance (7, 8) . Although the precise mechanism of action of these drugs remains unclear, recent literature reports the ability of TZDs to influence the expression of regulatory genes involved in adipocyte differentiation and proliferation, presumably via PPAR-␥ activation. In rodent adipose tissue and adipocyte cell cultures, the administration of TZDs results in increased expression of fatty acid transport protein (FATP), acyl-coenzyme A synthetase (ACS) (9) , and lipoprotein lipase (LPL) (10) , all of which contain functional PPAR response elements. It has been suggested that by stimulating the differentiation of adipocytes and increasing the sequestration of lipid into fat cells, lipid is less available in muscle and other tissues, where its accumulation and metabolism might otherwise contribute to insulin resistance (11, 12) . Although the expression of PPAR-␥ has been reported in skeletal muscle (2, 13, 14) , little is known about the potential effects of PPAR-␥ on gene regulation in this tissue. Furthermore, it has been suggested that accurate determination of PPAR-␥ expression in skeletal muscle is not possible due to contamination of samples with adipose tissue, in which the expression of PPAR-␥ is manyfold greater (14, 15) .
We have examined the messenger ribonucleic acid (mRNA) concentration of PPAR-␥ and other genes that might influence im lipids in freeze-dried human skeletal muscle dissected free of adipose tissue contamination. In this report we show that PPAR-␥ is expressed in human skeletal muscle and that the expression of three genes important in lipid metabolism, LPL, muscle carnitine palmitoyl transferase-1 (mCPT1), and fatty acid-binding protein (FABP) correlates with the expression of PPAR-␥ in these muscle samples. These data provide supportive evidence that PPAR-␥ might contribute to the antidiabetic effects of TZDs by regulating lipid metabolism genes in skeletal muscle as well as in adipose tissue.
Materials and Methods

Subject selection
The protocol was approved by the St. Vincent's Hospital human research ethics Committee. Fourteen healthy volunteers were selected on the basis that they were scheduled to undergo elective knee surgery. Volunteers were excluded if they had a history of cardiovascular disease or if they had clinically significant hepatic, renal, or hematological disease based on routine laboratory panels obtained during the screening visit.
Written informed consent was obtained after all procedures were explained to each subject. The subjects were elderly men (aged 68.1 Ϯ 1.3 yr) and, as a group, slightly overweight. They represent the range of insulin sensitivities and body composition expected from a normal aging population. The clinical characteristics of the subjects are presented in Table 1 . Elective knee surgery was performed at St. Vincent's Hospital (Darlinghurst, Sydney, Australia). After an overnight fast, general anesthesia was induced by a short-acting barbiturate and was maintained by alfentanil-hydrochloride. A tissue biopsy (ϳ1 g) of the vastus lateralis muscle was taken at the beginning of the surgical procedure, avoiding measures that might create ischemia. The biopsies were divided into aliquots, snap-frozen in liquid nitrogen, and stored at Ϫ80 C until required.
Preparation of freeze-dried and dissected human skeletal muscle
Approximately 50 mg wet weight vastus lateralis skeletal muscle was freeze-dried under vacuum for 24 h. After freeze-drying, the muscle sample was viewed under a microscope (ϫ6.3 magnification) at room temperature for careful dissection and removal of all traces of adipose tissue, connective tissue, and blood contaminants. On the average, this preparation yielded approximately 10 mg dry weight dissected skeletal muscle.
RNA isolation, extraction, and quantitation
Total RNA was extracted and purified from approximately 10 mg freeze-dried and dissected muscle using a guanidinium thiocyanatephenol technique (Tri-Reagent, Sigma, St. Louis, MO), according to the manufacturer's instructions. After extraction, RNA samples were treated with ribonuclease-free deoxyribonuclease (Promega Corp., Madison, WI). Total RNA yields were determined and standardized to 0.2 mg/mL by correlation to a standard RNA concentration curve, using a SYBR Green II (Molecular Probes, Inc., Eugene, OR) RNA standard assay (16) .
Semiquantitative RT-PCR
First strand complementary DNA was generated from 0.2 g RNA in a 10-L volume using random hexamers as primers (SuperScript, Life Technologies, Inc., Gaithersburg, MD). One microliter of the RT reaction mix was amplified with primers specific for human PPAR-␥, LPL, mCPT1, FABP, carnitine acyl carnitine transferase (CACT), glucose transporter-4 (GLUT4), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and adipsin. PPAR-␥ mRNA expression in human skeletal muscle was studied using PCR primer pairs designed by Vidal-Puig et al. (13) , which amplified a region common to both PPAR-␥1 and PPAR-␥2. All primer sequences and PCR conditions are shown in Table 2 . The linearity of the PCR was tested by amplification of 1 L of the RT reaction from 25-40 cycles. The linear range was between 25-38 cycles. The samples were amplified with AmpliTaq Gold (Perkin-Elmer Corp.-Cetus, Palo Alto, CA) for 25-38 cycles after an initial activation of 93 C for 10 min, using the following parameters: 93 C for 30 s, 50 -60 C for 30 s (see Table 2 ), and 72 C for 30 s. GAPDH was amplified as a control gene. Controls for genomic DNA contamination were included. To test for the presence of fat contamination in freeze-dried and dissected muscle biopsy samples, the abundance of adipsin mRNA was determined by PCR amplification using the same or a greater number of cycles required to amplify target genes. The same cycle number detected adipsin mRNA expression from control human adipose tissue preparations. The amplified products were size fractionated on a 2.5% agarose gel and stained with 0.5 g/mL ethidium bromide. The agarose gel was visualized under UV light, and the image was captured using the Molecular Analyst software package on the Gel Doc 1000 gel documentation image system (Bio-Rad Laboratories, Inc., Hercules, CA). The densities of the PCR products were measured using NIH Image software (version 1.61). Levels of mRNA were expressed as the ratio of signal intensity for the target genes relative to that for GAPDH. Median densities from 4 -8 separate PCR determinations from duplicate RT reactions were used to construct the correlations.
Statistical analysis
Subject characteristics are expressed as the mean Ϯ se (unless specifically noted). Coexpression of genes was assessed by simple linear regression analyses using StatView 4.51 (Abacus Concepts, Inc., Berkeley, CA); P Ͻ 0.05 was considered significant.
Results
Using semiquantitative RT-PCR analyses from the 14 individuals in this study, we obtained mRNA expression of PPAR-␥, LPL, mCPT1, FABP, CACT, GLUT4, and GAPDH in human skeletal muscle. Figure 1 shows representative experiments from 6 of the 14 subjects, demonstrating the range of variation in mRNA concentrations that were observed between individuals. Overall, we observed up to 3-fold variation in PPAR-␥ mRNA expression, 6.5-fold variation in LPL, 13-fold variation in mCPT1, 3-fold variation in GLUT4, and up to 4-fold variation in both FABP and CACT mRNA expression. Figure 1 also demonstrates very low or no adipsin mRNA expression in the muscle samples when amplified at the same or a greater number of PCR cycles as that required to amplify the target genes. This suggests that the PCR products we measured reflected mRNA expression in skeletal muscle only.
To identify any correlations of these genes to PPAR-␥, which could imply potential regulation by PPAR-␥, the expression of all genes of interest was first corrected for the expression of GAPDH. We then compared the mRNA expression of our target genes to the PPAR-␥ mRNA expression. The PPAR-␥ mRNA expression was significantly correlated with the mRNA expression of LPL (r 2 ϭ 0.54; P ϭ 0.003, Fig. 2a ), mCPT1 (r 2 ϭ 0.42; P ϭ 0.012; Fig. 2b ), and FABP (r 2 ϭ 0.324; P ϭ 0.034; Fig. 2c ). No significant correlation was observed between the mRNA expression of PPAR-␥ and that of CACT (r 2 ϭ 0.182 P ϭ 0.129), and no significant correlation was observed between PPAR-␥ and GLUT4 (r 2 ϭ 0.106; P ϭ 0.256), a gene expressed in muscle but not expected to be regulated by PPAR-␥.
To determine whether metabolic parameters were influencing PPAR-␥ expression in skeletal muscle, the relationship between mRNA expression of PPAR-␥ and the clinical characteristics of the subjects were investigated. Simple linear regression analysis showed no significant correlation between age, body mass index (BMI), plasma glucose, and plasma insulin and plasma lipids (nonesterified fatty acids and triglycerides) and PPAR-␥ mRNA expression in the subject group (data not shown).
Discussion
Human skeletal muscle has previously been reported to express PPAR-␥ in low amounts under basal conditions, and PPAR-␥1 is thought to be the only or the predominant isoform present in this tissue (1, 13) . Despite the low abundance of PPAR-␥ in human skeletal muscle (Ͻ15% of that in adipose tissue) (17) , there have been a number of studies focusing on the expression of PPAR-␥ in this tissue because of the central role of skeletal muscle in the development of insulin resistance in obese and type 2 diabetic subjects. Several recent reports suggest that the evaluation of PPAR-␥ expression in samples of human skeletal muscle is compromised by possible contamination of the muscle by adipose tissue (15) . This problem can be overcome to some extent by the use of primary human skeletal muscle myoblast cultures (14) or by monitoring the extent of adipose tissue contamination by measuring the expression of adipocyte-specific genes, such as adipocyte protein 2 or adipsin (1, 13, 17) . We applied a different approach by freeze-drying skeletal muscle samples and microscopically dissecting away any adipose tissue and connective tissue contamination. Thus, the variations in mRNA expression we report here for PPAR-␥, LPL, mCPT1, FABP, CACT, and GLUT4 probably reflect differential expression in skeletal muscle only. The lack of adipsin expression in dissected muscle highlights the lack of adipocyte contamination in muscle biopsy samples treated in this way. The observation that human skeletal muscle only expresses low amounts of PPAR-␥ raises the question of whether PPAR-␥ in muscle has any role in improving insulin sensitivity after TZD treatment. In rodents, one study reported that TZD administration resulted in a small induction of FATP mRNA expression and an induction of ACS mRNA expression in skeletal muscle (9) , suggesting a regulatory role for PPAR-␥ in this tissue. We have demonstrated in human skeletal muscle a significant correlation of PPAR-␥ expression with LPL and FABP expression. Furthermore, we have demonstrated that PPAR-␥ expression correlated significantly with the expression of mCPT1, an essential gene in the fatty acid ␤-oxidation pathway. Recently, a transcriptionally active PPAR response element has been identified upstream of mCPT1 (18) . This provides supportive evidence that this gene may be a target for the action of PPAR-␥. Overall, these findings imply that PPAR-␥ may play a role in the regulation of lipid metabolism genes in skeletal muscle by up-regulating the amounts of LPL, FABP, and mCPT1 in a coordinated fashion, which would serve to increase the oxidation of fatty acids in muscle. Although an increase in fatty acid oxidation in this tissue would seem to be contradictory to an improvement of insulin action (19) , it is possible that such a change in metabolism would eventually lead to decreased lipid availability in muscle, particularly if PPAR-␥-mediated actions were partitioning lipid into adipose tissue and reducing circulating lipid availability at the same time. The time required for the beneficial action of the TZDs to develop in humans (1-3 weeks) (8) suggests that there is considerable adaptation in metabolism required for the PPAR-␥ activators to exert their effects.
In adipose tissue, regulation of PPAR-␥ mRNA expression has shown to be influenced by insulin and obesity (13, 20, 21) . Similar investigations with respect to skeletal muscle PPAR-␥ expression have been less conclusive. Significant positive correlations have been reported between skeletal muscle PPAR-␥ mRNA levels and BMI and between PPAR-␥ and fasting insulin concentrations using obese and type 2 diabetic and lean nondiabetic control subjects (14) . However, other investigations have shown that skeletal muscle PPAR-␥ mRNA expression does not differ between normal and type 2 diabetic subjects, and that PPAR-␥ expression is not induced by short-term hyperinsulinemia (17) . In our study skeletal muscle PPAR-␥ mRNA concentrations varied up to 3-fold; however, these variations did not correlate with BMI, plasma insulin, or plasma fatty acids in our subject group. Thus, it could be argued that in this population, these metabolic factors are not determinants of increased PPAR-␥ and other lipid metabolism gene mRNA levels. However, it is possible that PPAR-␥ and the other measured transcripts are being influenced by another unknown or unmeasured factor.
In summary, we identified variation in mRNA expression of PPAR-␥, LPL, mCPT1, FABP, CACT, and GLUT4 in human skeletal muscle and report that the expression of LPL, mCPT1, and FABP is positively correlated with PPAR-␥ mRNA expression in this tissue. These data would be consistent with a hypothesis that TZDs may in part improve insulin action directly in skeletal muscle by stimulating the expression and action of PPAR-␥ and modulating fatty acid metabolism in muscle (22) . The implications of these findings for therapeutic agents in the treatment of diabetes and obesity warrant further investigation.
